Adverse Drug Reactions and Safety Considerations of NSAIDs: Clinical Analysis

被引:11
作者
Bahadur, Shiv [1 ]
Keshri, Lav [1 ]
Pathak, Kamla [1 ]
机构
[1] Rajiv Acad Pharm, Dept Pharmaceut, Mathura 281001, Uttar Pradesh, India
关键词
Adverse effects; COX-2; inhibitors; COX-3; drug safety; NSAIDs; non-selective NSAIDs;
D O I
10.2174/157488611798918683
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
NSAIDs are the most frequently used drugs for treatment, in Europe and the United States, accounting for approximately 5% of all prescriptions. Moreover, the use of NSAIDs is increasing because these constitute the first-line drug therapy for a wide range of rheumatic conditions. This increase is in part the result of the increasing population of elderly patients, who constitute the group of patients with greatest demand for these agents. There are many types of NSAIDs that vary in potency, action and potential side effects. Thus various efforts have been made to determine the safety considerations including adverse drug effects, duration of drug therapy, drug interactions, precautions and other drugs applied to reduce side effects. Researchers have introduced some novel techniques to diagnose NSAIDs related adverse effects on the gastrointestinal mucosa. The researchers dealing with the development of drug delivery system for these drugs should aim at designing a therapeutically efficacious dosage form with reduced side/adverse effects. Thus an effort has been made in this review to deal with the safety parameters of various NSAIDs with a special emphasis on preclinical and clinical safety analysis and various attempts to minimize the side effects by structural modification or by drug delivery system.
引用
收藏
页码:310 / 317
页数:8
相关论文
共 44 条
[1]   Antipyretics: Mechanisms of action and clinical use in fever suppression [J].
Aronoff, DM ;
Neilson, EG .
AMERICAN JOURNAL OF MEDICINE, 2001, 111 (04) :304-315
[2]   Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].
Bombardier, C ;
Laine, L ;
Reicin, A ;
Shapiro, D ;
Burgos-Vargas, R ;
Davis, B ;
Day, R ;
Ferraz, MB ;
Hawkey, CJ ;
Hochberg, MC ;
Kvien, TK ;
Schnitzer, TJ ;
Weaver, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528
[3]  
Botting R, 2000, J PHYSIOL PHARMACOL, V51, P609
[4]   COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression [J].
Chandrasekharan, NV ;
Dai, H ;
Roos, KLT ;
Evanson, NK ;
Tomsik, J ;
Elton, TS ;
Simmons, DL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (21) :13926-13931
[5]  
Chopra A., 2004, INT J RHEUM DIS, V7, P108
[6]  
Cole AT, 1999, ALIMENT PHARM THERAP, V13, P187
[7]   Risk-Benefit Perspectives in COX-2 Blockade [J].
Dabu-Bondoc, Susan ;
Franco, Samantha .
CURRENT DRUG SAFETY, 2008, 3 (01) :14-23
[8]  
Dammann HG, 1999, ALIMENT PHARM THER, V13, P1109
[9]  
Dammann HG, 1999, PREFERENTIAL COX 2 I, V37, P45
[10]   Long-term Use of Anti-inflammatory Drugs and Risk of Atrial Fibrillation [J].
De Caterina, Raffaele ;
Ruigomez, Ana ;
Garcia Rodriguez, Luis Alberto .
ARCHIVES OF INTERNAL MEDICINE, 2010, 170 (16) :1450-1455